Trial · NCT03712878
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
NCT03712878, Phase 2, Completed, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies. Trials, record NCT03712878. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03712878
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
- NCT number
- NCT03712878
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm
- Interventions
- Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide, Allogeneic Hematopoietic Stem Cell Transplantation, Tacrolimus, Mycophenolate Mofetil
- First posted
- 2018-10-19
- Last updated
- 2026-07-23
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Donor T Cell Chimerism Values Greater Than or Equal to 98% | At day +28 | Donor T cell chimerism (defined by 98% or greater donor T cell chimerism) by 28 days post HSCT (d+28). All estimates of rates will be presented with corresponding 95% confidence intervals. For chimerism rates, the method of Atkinson and Brown will be used to allow for the two-stage design. |
| Secondary | Percentage of Participants With Donor T Cell Chimerism Values Greater Than or Equal to 98% | At day +90 | Will be presented with corresponding 95% confidence intervals. For chimerism rates, the method of Atkinson and Brown will be used to allow for the two-stage design. |
| Secondary | Relapse Rate | At 1 year post-hematopoietic stem cell transplantation (HSCT) | Will be presented with corresponding 95% confidence intervals. |
| Secondary | Percentage of Participants With Grades II-IV Graft Versus Host Disease (GVHD) | Within 1 year of HSCT | Will be presented with corresponding 95% confidence intervals. |
| Secondary | Rate of Treatment-related Mortality (TRM) | At 1 year post-HSCT | Will be presented with corresponding 95% confidence intervals. |
| Other | Rate of Cytomegalovirus | Up to 100 days | Rate of cytomegalovirus |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03712878
GET https://conductscience.org/api/trials/v1/NCT03712878/registered